Free Trial

Allogene Therapeutics (ALLO) Stock Price, News & Analysis

Allogene Therapeutics logo
$1.29 +0.01 (+0.78%)
Closing price 04:00 PM Eastern
Extended Trading
$1.28 -0.01 (-0.78%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Allogene Therapeutics Stock (NASDAQ:ALLO)

Key Stats

Today's Range
$1.25
$1.30
50-Day Range
$0.95
$1.62
52-Week Range
$0.86
$3.78
Volume
1.79 million shs
Average Volume
4.27 million shs
Market Capitalization
$282.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.44
Consensus Rating
Moderate Buy

Company Overview

Allogene Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
72nd Percentile Overall Score

ALLO MarketRank™: 

Allogene Therapeutics scored higher than 72% of companies evaluated by MarketBeat, and ranked 286th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Allogene Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Allogene Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Allogene Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Allogene Therapeutics are expected to decrease in the coming year, from ($1.28) to ($1.35) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Allogene Therapeutics is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Allogene Therapeutics is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Allogene Therapeutics has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Allogene Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    13.99% of the float of Allogene Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Allogene Therapeutics has a short interest ratio ("days to cover") of 8.1.
  • Change versus previous month

    Short interest in Allogene Therapeutics has recently increased by 2.04%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Allogene Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Allogene Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.99% of the float of Allogene Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Allogene Therapeutics has a short interest ratio ("days to cover") of 8.1.
  • Change versus previous month

    Short interest in Allogene Therapeutics has recently increased by 2.04%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Allogene Therapeutics has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.01 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Allogene Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    6 people have searched for ALLO on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Allogene Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Allogene Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,537.00 in company stock.

  • Percentage Held by Insiders

    13.20% of the stock of Allogene Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    83.63% of the stock of Allogene Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Allogene Therapeutics' insider trading history.
Receive ALLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALLO Stock News Headlines

3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.
See More Headlines

ALLO Stock Analysis - Frequently Asked Questions

Allogene Therapeutics' stock was trading at $2.13 at the beginning of the year. Since then, ALLO shares have decreased by 39.4% and is now trading at $1.29.

Allogene Therapeutics, Inc. (NASDAQ:ALLO) posted its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.28) EPS for the quarter, hitting the consensus estimate of ($0.28).
Read the conference call transcript
.

Allogene Therapeutics (ALLO) raised $272 million in an IPO on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies served as the underwriters for the IPO.

Top institutional shareholders of Allogene Therapeutics include Kingstone Capital Partners Texas LLC (0.16%). Insiders that own company stock include David D Chang, Arie Belldegrun, Geoffrey M Parker, Earl Martin Douglas, Veer Bhavnagri, Rafael Amado, Zachary Roberts, Franz B Humer, Timothy L Moore, Owen N Witte, Benjamin Machinas Beneski, Annie Yoshiyama and Stephen Mayo.
View institutional ownership trends
.

Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Allogene Therapeutics investors own include Waste Connections (WCN), American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
5/13/2025
Today
7/14/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ALLO
CIK
1737287
Fax
N/A
Employees
310
Year Founded
2018

Price Target and Rating

High Price Target
$14.00
Low Price Target
$4.00
Potential Upside/Downside
+559.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.23)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$257.59 million
Net Margins
N/A
Pretax Margin
-1,168,850.00%
Return on Equity
-52.98%
Return on Assets
-41.28%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.71
Quick Ratio
9.71

Sales & Book Value

Annual Sales
$20 thousand
Price / Sales
13,998.72
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.01 per share
Price / Book
0.64

Miscellaneous

Outstanding Shares
218,730,000
Free Float
189,859,000
Market Cap
$279.97 million
Optionable
Optionable
Beta
0.31

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ALLO) was last updated on 7/14/2025 by MarketBeat.com Staff
From Our Partners